Reference health

Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB<sub>1</sub> and CB<sub>2</sub> Receptors

https://doi.org/10.1021/cn200114w
CiteStamped reference-health badge
27/27 checkable references clean · checked 2026-07-22

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

The 27 checked references that resolve
resolves10.1007/978-1-4419-6448-9_5
Huntington’s Disease
resolves10.1152/physrev.00041.2009
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
resolves10.1093/hmg/ddq148
Huntington's disease: progress toward effective disease-modifying treatments and a cure
resolves10.2174/138161208785740108
The Endocannabinoid System in Huntingtons Disease
resolves10.1517/14728221003709792
The endocannabinoid system as a target for the treatment of neuronal damage
resolves10.1097/00001756-200410250-00015
Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo
resolves10.1111/j.1460-9568.2007.05717.x
Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid<i>in vivo</i>by mechanisms independent of the activation of cannabinoid, vanilloid TRPV<sub>1</sub>and adenosine A<sub>2A</sub>receptors
resolves10.1093/brain/awq278
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease
resolves10.1093/brain/awp239
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
resolves10.1002/glia.20838
Cannabinoid CB<sub>2</sub>receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease
resolves10.1016/j.neuropharm.2006.06.013
The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum
resolves10.1016/j.neuroscience.2010.06.056
Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice
resolves10.1586/ern.11.47
THC and CBD oromucosal spray (Sativex<sup>®</sup>) in the management of spasticity associated with multiple sclerosis
resolves10.2165/11539000-000000000-00000
Role of Cannabinoids in Multiple Sclerosis
resolves10.1111/j.1476-5381.2008.00048.x
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
resolves10.1002/jnr.22682
Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease
resolves10.1093/hmg/ddq026
Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression
resolves10.1016/0091-3057(91)90386-G
Controlled clinical trial of cannabidiol in Huntington's disease
resolves10.1176/jnp.2006.18.4.553
Nabilone Could Treat Chorea and Irritability in Huntington’s Disease
resolves10.1002/mds.22809
A pilot study using nabilone for symptomatic treatment in Huntington's disease
resolves10.1002/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7
Nabilone increases choreatic movements in Huntington's disease
resolves10.1212/WNL.0b013e3181e62076
High insulinlike growth factor I is associated with cognitive decline in Huntington disease
resolves10.1212/01.wnl.0000222734.56412.17
Microglial activation correlates with severity in Huntington disease
resolves10.1016/j.mehy.2005.08.026
A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol
resolves10.1097/00001756-200305060-00007
Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate
resolves10.1016/j.tips.2006.11.001
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
resolves10.1203/PDR.0b013e318186e5dd
Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1021/cn200114w"><img src="https://citestamp.com/citestamped/10.1021/cn200114w/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1021/cn200114w/badge.svg)](https://citestamp.com/citestamped/10.1021/cn200114w)